Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
5e5 of anti-CLEC12A/CLL-1 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CLEC12A, His Tag (Cat. No. CLA-HP2Q3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Immobilized Biotinylated Human CLEC12A, His,Avitag (Cat. No. CLA-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Monoclonal Anti-Human CLEC12A Antibody, Human IgG1 with a linear range of 0.1-0.8 ng/mL (QC tested).
The purity of Human CLEC12A, Fc Tag (Cat. No. CLA-H5266) was more than 90% and the molecular weight of this protein is around 125-140 kDa verified by SEC-MALS.
Immobilized Human CLEC12A, Fc Tag (Cat. No. CLA-H5266) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human CLEC12A Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University) | Phase 3 Clinical | Fujian Medical University | Leukemia, Myeloid, Acute | Details | |
| ICG-136 | ICG-136 | Phase 1 Clinical | Icell Gene Therapeutics | Leukemia, Myeloid, Acute | Details |
| CLL-1.CAR T cell therapy (Baylor College of Medicine) | Phase 1 Clinical | Baylor College Of Medicine | Leukemia, Myeloid, Acute | Details | |
| Anti-CD33/CLL-1 CAR-T (Legend) | Phase 1 Clinical | Leukemia, Promyelocytic, Acute | Details | ||
| Tepoditamab | MCLA-117 | Phase 1 Clinical | Pharmaceutical Research Associates, Merus, Vu University Medical Center, Lgc, Institute Gustave-Roussy | Leukemia, Myeloid, Acute | Details |
| CLL1-CD33 cCART cell therapy (iCell Gene Therapeutics) | CLL1-CD33-cCAR | Phase 1 Clinical | Icell Gene Therapeutics, Chengdu Military General Hospital | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hematologic Neoplasms; Myeloproliferative Disorders; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| Anti-CLL1 CAR T cell therapy (The First Affiliated Hospital of Soochow University) | Phase 2 Clinical | Leukemia, Myeloid, Acute | Details | ||
| KITE-222 | Phase 1 Clinical | Kite Pharma | Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.
A-Z
